Department of Health
COVID-19: Guidance on clinical trials for institutions, HRECs, researchers and sponsors
Audience: Research institutions, Human Research Ethics Committees, researchers and sponsors
Purpose: Guidance provides general information and advice to institutions conducting or overseeing research, Human Research Ethics Committees (HRECs), researchers and sponsors in the context of the COVID-19 pandemic.
Australian Clinical Trials Alliance (ACTA)
COVID-19 Resources for Clinical Trials
Audience: Patients, research participants, health care professionals, researchers and other staff involved in patient care and research
Purpose: Guidance on clinical trials during the COVID-19 pandemic.
Australia New Zealand Gynaecological Oncology Group (ANZGOG)
ANZGOG & COVID-19 Statement
Purpose: Statement about ANZGOG clinical trials.
FDA Oncology Center of Excellence
A message to patients with cancer and health care providers about COVID-19
Audience: Health care providers (and patients)
Purpose: Information about oncology drug production and clinical trials.
US Food & Drug Administration (FDA)
FDA guidance on conduct of clinical trials of medical products during COVID-19 public health emergency
Audience: Sponsors, clinical investigators, and institutional review boards
Purpose: Guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 public health emergency.
National Cancer Institute
Audience: Oncology community
Purpose: Guidance on managing clinical trials during the time of COVID-19.